NOBILIS RISMAVAC + CA126
NOBILIS RISMAVAC + CA126
Authorised
- Turkey herpesvirus, strain FC-126 (cell-associated), Live
- Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live
Product identification
Medicine name:
NOBILIS RISMAVAC + CA126
Active substance:
- Turkey herpesvirus, strain FC-126 (cell-associated), Live
- Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live
Target species:
-
Chicken
Route of administration:
-
In ovo
-
Intramuscular use
-
Subcutaneous use
Product details
Active substance and strength:
-
Turkey herpesvirus, strain FC-126 (cell-associated), Live3.00/log10 unit(s)0.20millilitre(s)
-
Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live3.00/log10 unit(s)0.20millilitre(s)
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
In ovo
-
Chicken
-
Meat0day
-
Egg0day
-
-
-
Intramuscular use
-
Chicken
-
Egg0day
-
Meat0day
-
-
-
Subcutaneous use
-
Chicken
-
Egg0day
-
Meat0day
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI01AD03
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Cyprus
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 8(3) of Directive No 2001/83/EC)
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Intervet International B.V.
Responsible authority:
- Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
- CY00052V
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 5/05/2023